Fig. 7From: Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathwayKLF-5 is the transcription factor of ABCA1. The double luciferase reporter gene assay showed that KLF-5 could bound to the promoter region of ABCA1, while mutant 2 ABCA1 is invalid. (Data presented are the mean ± S.D.; *P < 0.05 vs. OE-KLF5 + WT-ABCA1 + TK, n = 3)Back to article page